Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Global Glp 1 Analogues Market Market Size in USD Billion GLP-1 Analogues Market Size The global GLP-1 analogues market size was valued at USD 32.19 billion in 2024 and is expected to reach USD 346.06 billion by 2032 , at a CAGR of 34.56% during the forecast period This growth is driven by factors such as the rising global prevalence of obesity and type 2 diabetes, along with increasing adoption of GLP-1 analogues due to their effectiveness in glycemic control and weight management GLP-1 Analogues Market Analysis GLP-1 (glucagon-like peptide-1) analogues are injectable drugs used primarily for the treatment of type 2 diabetes and obesity, improving blood sugar control and aiding in weight loss by mimicking the GLP-1 hormone The market growth is significantly driven by the increasing global prevalence of obesity and type 2 diabetes, along with growing awareness of the benefits of GLP-1 analogues in weight management North America is expected to lead the GLP-1 analogues market with with an estimated market share of over 76.05%, due to high obesity rates, robust healthcare systems, and early adoption of advanced therapies Asia-Pacific is projected to witness the fastest growth owing to rising diabetic population, healthcare access improvements, and expanding awareness of chronic disease management Ozempic segment is expected to dominate the market with a market share of 34.67% due to its proven efficacy in lowering HbA1c levels and promoting significant weight loss in patients with type 2 diabetes
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
A More Personalized Approach To Weight Loss
However, exceptions were made for medications treating conditions like AIDS wasting and cachexia, recognizing their broader therapeutic benefits
Kennedy reported that the absence of PTP-1B in mice resulted in a resistance to obesity (63)
Due to supply constraints and commissioning restrictions, many patients currently access these medications through private prescription
